A Summary of the HCC-CARE Symposium: Collaborative Approaches to Reaching Equity in Hepatocellular Carcinoma in Boston by 2030
- PMID: 40726621
- PMCID: PMC12301847
- DOI: 10.2147/JHC.S528033
A Summary of the HCC-CARE Symposium: Collaborative Approaches to Reaching Equity in Hepatocellular Carcinoma in Boston by 2030
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality in the United States. Disparities in HCC incidence and mortality are amplified in Boston, Massachusetts, which has 42% higher HCC mortality than the nation. HCC-CARE was a one-day symposium that aimed to identify goals and strategies necessary to eliminate HCC disparities in the Greater Boston area by 2030. Sixty-six local and state stakeholders attended the symposium, including HCC clinical experts (eg, medical oncologists) and primary care clinicians representing all seven of Boston's major cancer centers, ancillary staff members (eg, social workers) and state and local government agencies. The symposium included introductory sessions on HCC disparities, conceptual approaches to addressing disparities, and perspectives of local stakeholders on HCC disparities, followed by two interactive workshops where nine groups brainstormed and voted on goals, then developed preliminary action plans. Symposium participants identified four priority goals and developed associated action plans to eliminate HCC disparities by 2030: 1) improving HCC screening rates to enable early detection, 2) employing community engagement and outreach to communities at high risk of HCC, 3) developing a multi-institutional HCC registry to inform care delivery improvements, and 4) connecting patients with HCC to support services to address common barriers to care. A fifth priority around addressing disparities in HCC treatment emerged from post-symposium feedback. HCC-CARE established a knowledge base and raised the saliency of HCC disparities among participants, created a multi-institutional consortium of individuals committed to addressing HCC disparities, and leveraged the wide-ranging expertise of the participants to identify key goals and strategies for achieving equity in HCC outcomes by 2030. These strategies require further development and implementation through multi-institutional committees established after the symposium for each priority area. The Symposium represented a key first step in launching coordinated efforts to reduce HCC disparities that other cities may emulate.
Keywords: health equity; hepatocellular carcinoma.
© 2025 Lau-Min et al.
Conflict of interest statement
KSL has received honoraria from Wiley and has an immediate family member who is employed by and owns stock in GlaxoSmithKline. AB reports consulting with Agenus and Sirtex and conducts institutional research with Seagen, AstraZeneca, Agenus and Geistlich. CM reports funding related to hepatocellular carcinoma disparities from the American Cancer Society, Flatiron Health and AstraZeneca. The authors report no other conflicts of interest in this work.
Figures
References
- 
    - Dana Farber Cancer Institute. Dana-Farber Cancer Institute Community needs assessment executive summary, 2020-2023; 2020. Available from: https://www.dana-farber.org/community-health/community-health-needs-asse.... Accessed July 9, 2025.
 
LinkOut - more resources
- Full Text Sources
 
         
              